Suning Chen1,2, Stefan Nagel1, Bjoern Schneider1,3, Haiping Dai1,2, Robert Geffers4, Maren Kaufmann1, Corinna Meyer1, Claudia Pommerenke1, Kenneth S Thress5, Jiao Li6, Hilmar Quentmeier1, Hans G Drexler1, Roderick A F MacLeod7. 1. Department of Human and Animal Cell Lines, DSMZ - German Collection of Microorganisms and Cell Cultures, Inhoffenstrasse 7b, 38124, Braunschweig, Germany. 2. Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. 3. Institute of Pathology and Molecular Pathology, University of Rostock, Rostock, Germany. 4. Genome Analytics Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany. 5. AstraZeneca Oncology Innovative Medicines, Waltham, MA, USA. 6. Department of Hematology, Yixing People's Hospital of Jiangsu Province, Yixing, People's Republic of China. 7. Department of Human and Animal Cell Lines, DSMZ - German Collection of Microorganisms and Cell Cultures, Inhoffenstrasse 7b, 38124, Braunschweig, Germany. rafmacleod@gmail.com.
Abstract
BACKGROUND: Previously, the chromosomal translocation t(12;15)(p13;q25) has been found to recurrently occur in both solid tumors and leukemias. This translocation leads to ETV6-NTRK3 (EN) gene fusions resulting in ectopic expression of the NTRK3 neurotropic tyrosine receptor kinase moiety as well as oligomerization through the donated ETV6-sterile alpha motif domain. As yet, no in vitro cell line model carrying this anomaly is available. Here we genetically characterized the acute promyelocytic leukemia (APL) cell line AP-1060 and, by doing so, revealed the presence of a t(12;15)(p13;q25). Subsequently, we evaluated its suitability as a model for this important clinical entity. METHODS: Spectral karyotyping, fluorescence in situ hybridization (FISH), and genomic and transcriptomic microarray-based profiling were used to screen for the presence of EN fusions. qRT-PCR was used for quantitative expression analyses. Responses to AZ-23 (NTRK) and wortmannin (PI3K) inhibitors, as well as to arsenic trioxide (ATO), were assessed using colorimetric assays. An AZ-23 microarray screen was used to define the EN targetome, which was parsed bioinformatically. MAPK1 and MALAT1 activation were assayed using Western blotting and RNA-FISH, respectively, whereas an AML patient cohort was used to assess the clinical occurrence of MALAT1 activation. RESULTS: An EN fusion was detected in AP1060 cells which, accordingly, turned out to be hypersensitive to AZ-23. We also found that AZ-23 can potentiate the effect of ATO and inhibit the phosphorylation of its canonical target MAPK1. The AZ-23 microarray screen highlighted a novel EN target, MALAT1, which also proved sensitive to wortmannin. Finally, we found that MALAT1 was massively up-regulated in a subset of AML patients. CONCLUSIONS: From our data we conclude that AP-1060 may serve as a first publicly available preclinical model for EN. In addition, we conclude that these EN-positive cells are sensitive to the NTRK inhibitor AZ-23 and that this inhibitor may potentiate the therapeutic efficacy of ATO. Our data also highlight a novel AML EN target, MALAT1, which was so far only conspicuous in solid tumors.
BACKGROUND: Previously, the chromosomal translocation t(12;15)(p13;q25) has been found to recurrently occur in both solid tumors and leukemias. This translocation leads to ETV6-NTRK3 (EN) gene fusions resulting in ectopic expression of the NTRK3 neurotropic tyrosine receptor kinase moiety as well as oligomerization through the donated ETV6-sterile alpha motif domain. As yet, no in vitro cell line model carrying this anomaly is available. Here we genetically characterized the acute promyelocytic leukemia (APL) cell line AP-1060 and, by doing so, revealed the presence of a t(12;15)(p13;q25). Subsequently, we evaluated its suitability as a model for this important clinical entity. METHODS: Spectral karyotyping, fluorescence in situ hybridization (FISH), and genomic and transcriptomic microarray-based profiling were used to screen for the presence of EN fusions. qRT-PCR was used for quantitative expression analyses. Responses to AZ-23 (NTRK) and wortmannin (PI3K) inhibitors, as well as to arsenic trioxide (ATO), were assessed using colorimetric assays. An AZ-23 microarray screen was used to define the EN targetome, which was parsed bioinformatically. MAPK1 and MALAT1 activation were assayed using Western blotting and RNA-FISH, respectively, whereas an AMLpatient cohort was used to assess the clinical occurrence of MALAT1 activation. RESULTS: An EN fusion was detected in AP1060 cells which, accordingly, turned out to be hypersensitive to AZ-23. We also found that AZ-23 can potentiate the effect of ATO and inhibit the phosphorylation of its canonical target MAPK1. The AZ-23 microarray screen highlighted a novel EN target, MALAT1, which also proved sensitive to wortmannin. Finally, we found that MALAT1 was massively up-regulated in a subset of AMLpatients. CONCLUSIONS: From our data we conclude that AP-1060 may serve as a first publicly available preclinical model for EN. In addition, we conclude that these EN-positive cells are sensitive to the NTRK inhibitor AZ-23 and that this inhibitor may potentiate the therapeutic efficacy of ATO. Our data also highlight a novel AML EN target, MALAT1, which was so far only conspicuous in solid tumors.
Authors: J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Kenneth Thress; Terry Macintyre; Haiyun Wang; Dave Whitston; Zhong-Ying Liu; Ethan Hoffmann; Tao Wang; Jeffrey L Brown; Kevin Webster; Charles Omer; Peter E Zage; Lizhi Zeng; Patrick A Zweidler-McKay Journal: Mol Cancer Ther Date: 2009-06-09 Impact factor: 6.261
Authors: Johanna M Kralik; Wolfgang Kranewitter; Hans Boesmueller; Renate Marschon; Gertraud Tschurtschenthaler; Holger Rumpold; Kurt Wiesinger; Martin Erdel; Andreas L Petzer; Gerald Webersinke Journal: Diagn Pathol Date: 2011-03-15 Impact factor: 2.644
Authors: Haiping Dai; Stefan Ehrentraut; Stefan Nagel; Sonja Eberth; Claudia Pommerenke; Wilhelm G Dirks; Robert Geffers; Srilaxmi Kalavalapalli; Maren Kaufmann; Corrina Meyer; Silke Faehnrich; Suning Chen; Hans G Drexler; Roderick A F MacLeod Journal: PLoS One Date: 2015-11-23 Impact factor: 3.240
Authors: Alina-Andreea Zimta; Ciprian Tomuleasa; Iman Sahnoune; George A Calin; Ioana Berindan-Neagoe Journal: Front Oncol Date: 2019-10-18 Impact factor: 6.244
Authors: Jeffrey J Kooijman; Wilhelmina E van Riel; Jelle Dylus; Martine B W Prinsen; Yvonne Grobben; Tessa J J de Bitter; Antoon M van Doornmalen; Janneke J T M Melis; Joost C M Uitdehaag; Yugo Narumi; Yusuke Kawase; Jeroen A D M de Roos; Nicole Willemsen-Seegers; Guido J R Zaman Journal: Front Oncol Date: 2022-09-14 Impact factor: 5.738